Abstract:BackgroundBeckman Coulter developed a fully automated Access HIV Ag/Ab combo assay for the new DxI 9000 Access Immunoassay analyzer that reports separate results for HIV-1 p24 antigen (Ag) and HIV-1/2 antibody (Ab) with a 30 minute time to first result and a sample volume of only 60 μL. Evaluation of the Access HIV Ag/Ab combo assay assessed analytical sensitivity for seroconversion panels, HIV-1 p24 Ag (WHO I.S. NIBSC code 90/636), and HIV-1 and HIV-2 Ag from different viral strains. Clinical specificity and sensitivity of this 4 th generation assay was also assessed.MethodsThirty commercially available seroconversion panels were assessed on Access HIV Ag/Ab combo (3 lots), Abbott Architect HIV Ag/Ab Combo, and Roche Elecsys HIV Duo assays. The HIV-1 p24 Ag analytical sensitivity of the Access assay was performed on dilutions of HIV-1 p24 Ag WHO I.S. prepared in HIV negative human serum and plasma, ranging from 0.1 to 1.0 IU/mL. Fifty positive viral lysates from HIV-1 group M (A-H subtypes, CRF01, CRF02, CRF06, CRF11, CRF14, CRF15, CRF18, CRF36), HIV-1 group O (H and T subgroups), and HIV-2 (groups A and B) were spiked into HIV negative human CPD plasma and tested on both the Access and Architect assays. Clinical sensitivity and specificity were determined for the Access assay using the Architect assay as comparator by testing samples from HIV low risk, high risk and HIV known positive populations at three US clinical laboratories. An HIV 1/2 differentiation assay and HIV-1 RNA PCR were also run to confirm patient infection status.ResultsThe Access HIV Ag/Ab combo assay detected a higher number of bleeds (n=90) than the Elecsys (n = 80) and Architect (n = 77) assays due to earlier Ag detection. The average number of days between positive detection of a bleed previously identified Nucleic Acid Test (NAT) positive compared to these assays was reduced by 1.2 to 1.6 days (Access = 6.8 days; Elecsys = 8.0 days; Architect = 8.4 days). The Access assay also offered a limit of detection for the HIV-1 p24 Ag WHO I.S. between 0.19 and 0.22 IU/mL and a higher sensitivity for HIV-1 p24 Ag compared to the Architect assay: overall median Signal/Cut-Off (S/CO) for the 46 HIV-1 strains = 2.45 with the Access assay when the Architect assay S/CO was normalized at 1.00. HIV-2 strains were not included in this calculation since they were not detected by the Architect assay. A clinical validation study demonstrated 100.0% sensitivity for Access (n= 1,787; 95% CI: 99.8-100.0%) vs 99.8% for the Architect assay (n=1,786; 95% CI: 99.5-99.9%) and 99.7% specificity for Access (n=8,467; 95% CI: 99.5-99.8%) vs 98.8% for the Architect assay (n= 8,467, 95% CI: 98.6-99.0).ConclusionsThe new Access HIV Ag/Ab combo assay demonstrated excellent analytical performances, particularly its high HIV-1 p24 Ag sensitivity, which could help reduce the diagnosis window and thus prevent any delay of treatment for an infected patient. Furthermore, the Access assay showed clinical sensitivity and specificity performance meeting or exceeding that of currently marketed HIV combo immunoassays.

Evaluation of the mindray CL900i CLIA HIV Ag/Ab combo assay for sensitive and specific HIV screening compared to established methods

Evaluation of the Clinical Effectiveness of HIV Antigen/antibody Screening Using a Chemiluminescence Microparticle Immunoassay.

B-058 Multicenter Evaluation of the new Access HIV Ag/Ab combo Assay With Highly Sensitive HIV-1 p24 Antigen Detection on the DxI 9000 Access Immunoassay Analyzer

Performance Evaluation of the New Chemiluminescence Immunoassay CL-1200i for HBV, HIV Panels

Performance evaluation of the mindray anti-HCV assay for the detection of hepatitis C virus infection.

Clinical diagnostic performance of light-initiated chemiluminescent assay compared with the Architect chemiluminescence immunoassay for detection of HCV antibody.

Sensitivity and specificity of the new Bio-Rad HIV screening test, Access HIV combo V2

Clinical performance evaluation of an HIV Duo assay: From HIV screening to acute and non-acute HIV infection detection

Laboratory-based evaluation of the 4th-generation AlereTM HIV Combo rapid point-of-care test

Detection of HIV-1 P24 Antigen Using a Simple and Highly Sensitive Chemiluminescence Immunoassay

Analytical evaluation of the novel Mindray high sensitivity cardiac troponin I immunoassay on CL-1200i

A-365 Rapid HIV testing and confirmation reflex testing integration in Laboratory Information System (LIS) using a point-of-care glucometer

Development of a Rapid Automated Fluorescent Lateral Flow Immunoassay to Detect Hepatitis B Surface Antigen (HBsAg), Antibody to HBsAg, and Antibody to Hepatitis C

Evaluation of a point-of-care rapid HIV antibody test with insights into acute HIV symptomatology in a population with low prevalence

Comparative Evaluation of SARS-CoV-2 Rapid Immunochromatographic Test Assays with Chemiluminescent Immunoassay for the Diagnosis of COVID-19

Consistency Between Treponema pallidum Particle Agglutination Assay and Architect Chemiluminescent Microparticle Immunoassay and Characterization of Inconsistent Samples

Comparison of a dual antibody and antigen HCV immunoassay to standard of care algorithmic testing

Performance Evaluation of the MAGLUMI Hepatitis B Virus Surface Antigen Chemiluminescence Immunoassay.

Diagnostic performance evaluation of urine HIV-1 antibody rapid test kits in a real-life routine care setting in China

Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID‐19 patients

The Evaluation of Elecsys HIV Combi Reagent in Detecting HIV Antigen and Antibody